| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.025 | 0.6 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.6 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |